These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29632372)

  • 21. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
    Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.
    Ahmad Z; Nuermberger EL; Tasneen R; Pinn ML; Williams KN; Peloquin CA; Grosset JH; Karakousis PC
    J Antimicrob Chemother; 2010 Apr; 65(4):729-34. PubMed ID: 20123722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of tuberculosis in Haiti.
    Long R; Scalcini M; Ollé-Goig J
    Am J Public Health; 2001 Oct; 91(10):1546-7. PubMed ID: 11574298
    [No Abstract]   [Full Text] [Related]  

  • 25. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP; Ebrahim S; Pillay V
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.
    Chen C; Wicha SG; de Knegt GJ; Ortega F; Alameda L; Sousa V; de Steenwinkel JEM; Simonsson USH
    CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):787-797. PubMed ID: 28657202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.
    Swanson RV; Ammerman NC; Ngcobo B; Adamson J; Moodley C; Dorasamy A; Moodley S; Mgaga Z; Bester LA; Singh SD; Almeida DV; Grosset JH
    Antimicrob Agents Chemother; 2016 May; 60(5):2864-9. PubMed ID: 26926638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
    Dorman SE; Nahid P; Kurbatova EV; Goldberg SV; Bozeman L; Burman WJ; Chang KC; Chen M; Cotton M; Dooley KE; Engle M; Feng PJ; Fletcher CV; Ha P; Heilig CM; Johnson JL; Lessem E; Metchock B; Miro JM; Nhung NV; Pettit AC; Phillips PPJ; Podany AT; Purfield AE; Robergeau K; Samaneka W; Scott NA; Sizemore E; Vernon A; Weiner M; Swindells S; Chaisson RE;
    Contemp Clin Trials; 2020 Mar; 90():105938. PubMed ID: 31981713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
    Andries K; Gevers T; Lounis N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4540-4. PubMed ID: 20713662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data.
    Mudde SE; Ayoun Alsoud R; van der Meijden A; Upton AM; Lotlikar MU; Simonsson USH; Bax HI; de Steenwinkel JEM
    J Infect Dis; 2022 Jun; 225(11):1876-1885. PubMed ID: 33606880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
    Dorman SE; Nahid P; Kurbatova EV; Phillips PPJ; Bryant K; Dooley KE; Engle M; Goldberg SV; Phan HTT; Hakim J; Johnson JL; Lourens M; Martinson NA; Muzanyi G; Narunsky K; Nerette S; Nguyen NV; Pham TH; Pierre S; Purfield AE; Samaneka W; Savic RM; Sanne I; Scott NA; Shenje J; Sizemore E; Vernon A; Waja Z; Weiner M; Swindells S; Chaisson RE; ;
    N Engl J Med; 2021 May; 384(18):1705-1718. PubMed ID: 33951360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Present status of chemotherapy for tuberculosis.
    Grosset JH
    Rev Infect Dis; 1989; 11 Suppl 2():S347-52. PubMed ID: 2652251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
    Srivastava S; Deshpande D; Magombedze G; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S359-S364. PubMed ID: 30496465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrashort-course chemotherapy for culture-negative pulmonary tuberculosis--a qualified success.
    Cowie RL; Langton ME; Escreet BC
    S Afr Med J; 1985 Dec; 68(12):879-80. PubMed ID: 4071345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.